Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

Real‐world characteristics and treatment of cardiac transthyretin amyloidosis: A multicentre, observational study

Abstract Aims Data on the clinical profiles of patients with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) in the post‐approval era of tafamidis 61 mg are lacking. Study aims were characterization of contemporary ATTR‐CM patients, analysis of potential eligibility for the ‘Transthyretin Amyloid...

Full description

Saved in:
Bibliographic Details
Main Authors: Richard J. Nies, Svenja Ney, Ingrid Kindermann, Yvonne Bewarder, Angela Zimmer, Fabian Knebel, Katrin Hahn, Sebastian Spethmann, Peter Luedike, Lars Michel, Tienush Rassaf, Maria Papathanasiou, Stefan Störk, Vladimir Cejka, Amin Polzin, Fabian Voss, Malte Kelm, Bernhard Unsöld, Christine Meindl, Michael Paulus, Ali Yilmaz, Bishwas Chamling, Caroline Morbach, Roman Pfister
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:ESC Heart Failure
Subjects:
Cardiac amyloidosis
Cardiomyopathy
Heart failure
TTR
Transthyretin
Tafamidis
Online Access:https://doi.org/10.1002/ehf2.15126
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ehf2.15126

Similar Items